Enlivex Ltd
enlivex.comWhat Do They Do?
Develops Allocetra, an investigational therapy for osteoarthritis, and maintains a digital-asset treasury centered on RAIN.
20-F for FY2025, filed Mar 25, 2026We are a quality longevity company focused on advancing therapies designed to extend health span and improve quality of life, powered by a…View ↗
On November 24, 2025, in connection with the consummation of the Private Placement, we launched our new cryptocurrency and digital asset…View ↗
We are a quality longevity company focused on advancing therapies designed to extend health span and improve quality of life, powered by a…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed Mar 25, 2026
Who Are Their Customers?
If a candidate is approved, Enlivex plans to commercialize products through alliances or licensing with biotechnology companies and other strategic partners that can market and sell them; it may also consider building its own sales operation.
20-F for FY2025, filed Mar 25, 2026Marketing, Sales and CommercializationView ↗
How Are They Changing?
Clinical focus
The older report described Allocetra development for sepsis and solid tumors; the latest report centers clinical work on osteoarthritis, particularly knee disease.
20-F for FY2022, filed Apr 10, 2023 20-F for FY2025, filed Mar 25, 2026The Company is currently focused on two main clinical verticals: sepsis and solid tumors (the “Indications”). The Company believes that…View ↗
Added treasury strategy
The older report described Enlivex as a clinical-stage immunotherapy company; the latest report pairs its clinical program with a digital-asset treasury centered on RAIN.
20-F for FY2022, filed Apr 10, 2023 20-F for FY2025, filed Mar 25, 2026The Company is a clinical-stage macrophage reprogramming immunotherapy company, developing AllocetraTM, a universal, off-the-shelf cell…View ↗
Loading...
